DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Peripheral blood samples of 236 CP CML patients on first-line treatment with any approved TKI were also evaluated for circulating CD26+ LSCs during a routinely molecular response assessment according to ELN guidelines.